XBiotech, Inc. (XBIT) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

44.07 k

Shareholding (Mar 2025)

FII

1.38%

Held by 30 FIIs

DII

89.9%

Held by 9 DIIs

Promoter

0.00%

How big is XBiotech, Inc.?

22-Jun-2025

As of Jun 18, XBiotech, Inc. has a market capitalization of 79.57 million, classifying it as a Micro Cap company, with net sales of 0.00 million and a net profit of -39.41 million over the latest four quarters. The company reported shareholder's funds of 182.27 million and total assets of 199.09 million as of Dec 24.

What does XBiotech, Inc. do?

22-Jun-2025

XBiotech, Inc. is a clinical-stage biopharmaceutical company focused on developing True Human monoclonal antibodies for various diseases. It has a market cap of $79.57 million and reported a net profit loss of $11 million as of March 2025.

Who are in the management team of XBiotech, Inc.?

22-Jun-2025

As of March 2022, the management team of XBiotech, Inc. includes John Simard as Chairman, President, CEO, and Founder, with Jan-Paul Waldin as Lead Independent Director and Peter Libby, Donald MacAdam, and W. Thorpe McKenzie as Independent Directors.

Is XBiotech, Inc. overvalued or undervalued?

25-Jun-2025

As of November 9, 2023, XBiotech, Inc. is considered overvalued with a valuation grade of "does not qualify," showing significant financial deterioration, highlighted by a negative P/E ratio of -2.0190, negative returns on equity of -22.56%, and a year-to-date stock performance of -34.43% compared to the S&P 500's 2.44%.

Is XBiotech, Inc. technically bullish or bearish?

20-Sep-2025

As of September 5, 2025, XBiotech, Inc. is in a bearish trend, indicated by negative daily moving averages and MACD signals, with a year-to-date return of -30.13% compared to the S&P 500's 12.22%.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 84 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.88

Return on Equity

-16.27%

Price to Book

0.48

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-15.77%

6 Months

-13.15%

1 Year

-62.7%

2 Years

-36.93%

3 Years

-26.18%

4 Years

-77.29%

5 Years

-86.56%

XBiotech, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Is XBiotech, Inc. technically bullish or bearish?

As of 5 September 2025, the technical trend for XBiotech, Inc. has changed from mildly bearish to bearish. The current stance is bearish, with key indicators supporting this view being the daily moving averages indicating bearishness, and the monthly MACD and Bollinger Bands also showing bearish signals. The weekly KST is mildly bullish, but this is overshadowed by the overall bearish trend. In terms of performance, XBiotech has significantly underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -30.13% versus the S&P 500's 12.22%, and a one-year return of -63.20% compared to 17.14% for the index....

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

-6.88%

EBIT to Interest (avg)

-32.69

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.89

Sales to Capital Employed (avg)

0.01

Tax Ratio

0.10%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

16.09%

ROCE (avg)

ROE (avg)

39.22%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.51

EV to EBIT

1.49

EV to EBITDA

1.55

EV to Capital Employed

-3.59

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-22.56%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bullish

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

No Trend

Mildly Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 16 Schemes (8.72%)

Foreign Institutions

Held by 30 Foreign Institutions (1.38%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 83.49% vs -3.81% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.90",
          "val2": "-13.10",
          "chgp": "54.96%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.80",
          "val2": "-10.90",
          "chgp": "83.49%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -56.50% vs 25.23% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-40.70",
          "val2": "-35.80",
          "chgp": "-13.69%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.80",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-38.50",
          "val2": "-24.60",
          "chgp": "-56.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-5.90

-13.10

54.96%

Interest

0.00

0.10

-100.00%

Exceptional Items

0.00

Consolidate Net Profit

-1.80

-10.90

83.49%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 83.49% vs -3.81% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-40.70

-35.80

-13.69%

Interest

0.80

0.00

Exceptional Items

0.00

Consolidate Net Profit

-38.50

-24.60

-56.50%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -56.50% vs 25.23% in Dec 2023

All Annual Results

Company CV

About XBiotech, Inc.

XBiotech, Inc.

Pharmaceuticals & Biotechnology

XBiotech Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. It focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response. The Company has also developed a True Human monoclonal antibody discovery platform and manufacturing system. Xilonix is a therapeutic antibody, which specifically neutralizes interleukin-1 alpha (IL-1a). Its pipeline includes various human antibodies for treating diseases, such as cancer, vascular disease, inflammatory skin disease and diabetes. The Company has completed a Phase III study in Europe for the treatment of symptomatic colorectal cancer. It also investigated its lead product candidate in clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS).

Company Coordinates

Company Details

Building 4, 8201 E Riverside Dr Ste 100 , AUSTIN TX : 78744-1602

Tel: 1 512 3862930

Registrar Details

XBiotech, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is XBiotech, Inc.?

Watch in Real-Time

What does XBiotech, Inc. do?

Who are in the management team of XBiotech, Inc.?

Is XBiotech, Inc. overvalued or undervalued?

Is XBiotech, Inc. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Is XBiotech, Inc. technically bullish or bearish?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About XBiotech, Inc.

Company Coordinates